Loading clinical trials...
Loading clinical trials...
The Immunogenicity and Safety of COVID-19 and Influenza Vaccine Co-administration and Interval in Immunocompromised Hosts
Conditions
Interventions
Inactivated influenza vaccine (IIV) at baseline
COVID-19 Vaccines at a 3-month interval
+2 more
Locations
3
Canada
Maisonneuve -Rosemont Installation
Montreal, Quebec, Canada
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
Research Institute of McGill University Health Centre
Montreal, Quebec, Canada
Start Date
November 20, 2024
Primary Completion Date
March 31, 2027
Completion Date
March 31, 2027
Last Updated
March 10, 2026
NCT01386424
NCT06647069
NCT07484243
NCT07268326
NCT07291635
NCT06094010
Ruth Sapir-Pichhadze, B.Med.Sc, MD, MSc, PhD, FRCPC
CONTACT
5149341934ruth.sapir-pichhadze.med@ssss.gouv.qc.caLead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions